A detailed history of Raymond James Financial Services Advisors, Inc. transactions in Regenxbio Inc. stock. As of the latest transaction made, Raymond James Financial Services Advisors, Inc. holds 64,338 shares of RGNX stock, worth $476,101. This represents 0.0% of its overall portfolio holdings.

Number of Shares
64,338
Previous 62,443 3.03%
Holding current value
$476,101
Previous $730,000 7.67%
% of portfolio
0.0%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024

BUY
$10.49 - $14.39 $19,878 - $27,269
1,895 Added 3.03%
64,338 $674,000
Q2 2024

Jul 19, 2024

BUY
$11.51 - $21.53 $59,403 - $111,116
5,161 Added 9.01%
62,443 $730,000
Q1 2024

Apr 22, 2024

SELL
$12.17 - $24.61 $104,917 - $212,162
-8,621 Reduced 13.08%
57,282 $1.21 Million
Q4 2023

Jan 16, 2024

SELL
$12.89 - $20.82 $632,370 - $1.02 Million
-49,059 Reduced 42.67%
65,903 $1.18 Million
Q3 2023

Oct 24, 2023

BUY
$16.46 - $19.99 $823,921 - $1 Million
50,056 Added 77.12%
114,962 $1.89 Million
Q2 2023

Jul 25, 2023

BUY
$17.23 - $21.71 $398,340 - $501,913
23,119 Added 55.33%
64,906 $1.3 Million
Q1 2023

Apr 14, 2023

SELL
$18.08 - $24.55 $42,487 - $57,692
-2,350 Reduced 5.32%
41,787 $790,000
Q4 2022

Feb 08, 2023

SELL
$20.4 - $24.73 $220,279 - $267,034
-10,798 Reduced 19.66%
44,137 $1 Million
Q3 2022

Oct 25, 2022

SELL
$22.29 - $35.04 $28,063 - $44,115
-1,259 Reduced 2.24%
54,935 $1.45 Million
Q2 2022

Aug 12, 2022

SELL
$19.35 - $35.04 $63,893 - $115,702
-3,302 Reduced 5.55%
56,194 $1.39 Million
Q1 2022

May 11, 2022

BUY
$24.62 - $34.31 $240,414 - $335,037
9,765 Added 19.64%
59,496 $1.98 Million
Q4 2021

Feb 08, 2022

BUY
$30.19 - $40.28 $29,827 - $39,796
988 Added 2.03%
49,731 $1.63 Million
Q3 2021

Nov 02, 2021

BUY
$29.09 - $45.68 $205,433 - $322,592
7,062 Added 16.94%
48,743 $2.04 Million
Q2 2021

Aug 11, 2021

BUY
$32.46 - $40.48 $485,796 - $605,823
14,966 Added 56.02%
41,681 $1.62 Million
Q1 2021

May 14, 2021

BUY
$33.61 - $49.95 $897,891 - $1.33 Million
26,715 New
26,715 $911,000
Q1 2020

Apr 21, 2020

SELL
$21.5 - $54.2 $268,707 - $677,391
-12,498 Closed
0 $0
Q4 2019

Feb 12, 2020

SELL
$34.54 - $44.87 $324,848 - $422,002
-9,405 Reduced 42.94%
12,498 $512,000
Q3 2019

Nov 07, 2019

SELL
$31.84 - $50.88 $112,236 - $179,352
-3,525 Reduced 13.86%
21,903 $780,000
Q2 2019

Aug 06, 2019

BUY
$42.0 - $59.29 $451,626 - $637,545
10,753 Added 73.27%
25,428 $1.31 Million
Q1 2019

May 06, 2019

BUY
$40.82 - $62.45 $224,142 - $342,912
5,491 Added 59.79%
14,675 $841,000
Q4 2018

Feb 11, 2019

BUY
$39.11 - $75.15 $175,134 - $336,521
4,478 Added 95.16%
9,184 $385,000
Q3 2018

Nov 14, 2018

BUY
$65.0 - $82.15 $305,890 - $386,597
4,706 New
4,706 $355,000

Others Institutions Holding RGNX

About REGENXBIO Inc.


  • Ticker RGNX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,230,000
  • Market Cap $320M
  • Description
  • REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...
More about RGNX
Track This Portfolio

Track Raymond James Financial Services Advisors, Inc. Portfolio

Follow Raymond James Financial Services Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James Financial Services Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Raymond James Financial Services Advisors, Inc. with notifications on news.